Status: Closed
Activation Date: 2004FEB11
Closing Date: 2010MAR23
Phase: III
Description: A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Eligibility: Postmenopausal women at increased risk for the development of breast cancer are eligible for this study
Objective: To determine if exemestane reduces the incidence of invasive breast cancer compared with placebo
Participation: Open to member centres
Lay Description: After menopause when the ovaries stop making estrogen the body continues to make estrogen from skin, muscle and fat. Even though it is only present at low levels it continues to be very important in the development of breast cancer. A new drug, called exemestane, stops the supply of estrogen to pre-cancerous and cancerous cells and helps to prevent them from growing.
Primary Publication Show
Other Publications Show
Inventory
Hide Tissue Samples
| Disease Site | Trial Code | Patients Accrued | Patients - Blocks | Patients - Slides | Patients - Blocks and/or Slides |
| BREAST | MAP3 | 4560 | 31 | 82 | 89 |
(Core size is 0.6 mm)
Hide
Fluid Samples| Disease Site | Trial Code | Patients Accrued | TMA Blocks | Patients on TMA Blocks |
| BREAST | MAP3 | 4560 | 1 | 1 |
| Disease Site | Trial Code | Patients Accrued | Patients - Whole Blood | Patients - Cellular Component of Blood | Patients - DNA extracted from Blood | Patients - RNA extracted from Blood | Patients - Plasma | Patients - Serum | Patients - Urine | Patients - Buccal |
| BREAST | MAP3 | 4560 | 4143 | 0 | 547 | 0 | 5 | 4330 | 0 | 0 |